Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Medina

Vascular & Interventional Radiology Scottsdale, AZ Medical Doctor

NPI 1093764722 CMS profile 4750

9323 E Bahia Drive Ste 200, Ste 100, Scottsdale, AZ 85260

Open in the dashboard

General payments

$9,639

208 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Medina of Scottsdale, AZ is reported in the CMS Open Payments database as having received $9,639 across 208 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,101 31
2024 General $1,386 43
2023 General $2,375 21
2022 General $2,075 36
2021 General $332 18
2020 General $579 16
2019 General $1,790 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Medina
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to David Medina were reported at $1,101. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year David Medina Vascular & Interventional Radiology median Middle half National median
2019 $1,790 $422 $125–$1,555 $163
2020 $579 $200 $68–$652 $114
2021 $332 $280 $99–$866 $132
2022 $2,075 $433 $137–$1,497 $149
2023 $2,375 $506 $152–$2,019 $160
2024 $1,386 $556 $175–$1,930 $164
2025 $1,101 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $3,189 78 payments
  2. Bard Peripheral Vascular, Inc. $2,190 15 payments
  3. Medtronic, Inc. $1,248 50 payments
  4. Sirtex Medical Inc $692 13 payments
  5. Medtronic USA, Inc. $444 10 payments
  6. Terumo Medical Corporation $383 8 payments
  7. Inari Medical, Inc. $233 4 payments
  8. Penumbra, Inc. $214 3 payments
  9. Medtronic Vascular, Inc. $139 4 payments
  10. ImmunoGen, Inc. $125 1 payment
  11. Other $783 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,326 203 payments
  2. Consulting Fee $1,500 1 payment
  3. Travel and Lodging $812 4 payments
Products named General payments · program years 2019–2025
  1. OSTEOCOOL RF ABLATION SYSTEM $1,098 40 payments
  2. SIR-Spheres Microspheres $692 13 payments
  3. General - Embolics $505 7 payments
  4. General - Therapies $501 3 payments
  5. EMBOLD Fibered $416 7 payments
  6. OSTEOCOOL RF ABLATION $392 7 payments
  7. HydroPearl $265 5 payments
  8. ClotTriever $233 4 payments
  9. FlowTriever $233 4 payments
  10. Direxion $183 10 payments
  11. Other $2,961 98 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

43

Median for Interventional Radiology: 38

Drug cost

$221

Median for Interventional Radiology: $333

Branded share of claims

37.2%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 13 $77
Ciprofloxacin Hcl Generic 14 $74
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 16 $70

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELAHERE
  • ImmunoGen, Inc. $125
$125 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

208 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record